AstraZeneca Plc reported better-than-expected profit and revenue in the fourth quarter and forecast further gains, helped by ...

The AstraZeneca PLC ADR AZN advanced 2.86% to $70.94 Wednesday, on what proved to be an all-around favorable trading session ...

Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's ...

Astrazeneca PLC (AZN) on Thursday reported fourth-quarter earnings of $1.5 billion. On a per-share basis, the Cambridge, Britain-based company said it had net income of 48 cents. Earnings, adjusted ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities ...

AstraZeneca PLC on Thursday ended a strong year with better-than-expected fourth quarter earnings and said its pipeline would support further growth in 2025. The Cambridge-based pharmaceuticals firm ...

LOS ANGELES, CA / ACCESS Newswire / February 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

The AstraZeneca PLC ADR AZN slipped 1.27% to $69.86 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.20% to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...